Biontech Se ADR (BNTX)

$91.18 +1.76 (1.97%)
Market Cap 22.92B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.01
Volume 786,700
Avg Vol 1,174,132
Day's Range N/A - N/A
Shares Out 251.33M
Stochastic %K 96%
Beta 1.58
Analysts Strong Sell
Price Target $136.68

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
I_Hate_Stock_Twits
I_Hate_Stock_Twits Apr. 3 at 6:42 PM
$BNTX This is why Robert Malone resigned. This recruitment stumble is a sham. No one will ever have to face the music. Still will never invest in this garbage. Shameful.
0 · Reply
Davidendz
Davidendz Apr. 3 at 1:37 PM
Biotech gets called “scam” on volatility, but that’s noise. What matters is data and execution. Across names like $BVAXF $BIOV.CSE,$MRNA, $BNTX, and $NVAX, it’s the same cycle: filings, catalysts, then price moves. Clinical progress > headlines.
0 · Reply
taxplanr
taxplanr Apr. 1 at 8:36 PM
What do you make of this testimony in front of the German Bundestag? $PFE $BNTX $MRNA https://www.instagram.com/reel/DWmYyx1jm4u/?igsh=MTBud3hycjBvM2J4ZA==
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 1 at 4:17 PM
$PFE $BNTX $MRNA $NVAX $SPY
2 · Reply
taxplanr
taxplanr Apr. 1 at 2:09 PM
Gastric tumors shrinking with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-cc3?utm_source=post-email-title&publication_id=1385328&post_id=192824123&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Apr. 1 at 2:02 PM
Metastases shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-mebendazole-fenbendazole-e15?utm_source=post-email-title&publication_id=1385328&post_id=192811753&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Pillemann1
Pillemann1 Apr. 1 at 8:45 AM
$BNTX https://www.ecdc.europa.eu/en/covid-19/variants-concern SARS-CoV-2 variants of concern as of 27 March 2026 Variant classification serves as an important communication tool for alerting EU/EEA countries about the emergence of SARS-CoV-2 variants with concerning properties likely to impact the epidemiological situation in the EU/EEA. The ECDC Strategic Analysis of Variants in Europe (SAVE) Working Group is a multidisciplinary team comprising of ECDC Experts working in Respiratory Viruses, Microbiology, Bioinformatics, Mathematical Modelling, Epidemic Intelligence, Emergency Preparedness and Response and Vaccine-Preventable Diseases and Immunisation. Currently meetings are held once per month to assess the observed or predicted impact of currently circulating and newly emerging SARS-CoV-2 variants in the EU/EEA and globally.
0 · Reply
PolycarpFX
PolycarpFX Mar. 31 at 10:34 PM
$BNTX
0 · Reply
taxplanr
taxplanr Mar. 31 at 4:31 PM
Bone tumors shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-454?utm_source=post-email-title&publication_id=1385328&post_id=192576453&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
1 · Reply
taxplanr
taxplanr Mar. 30 at 2:17 PM
Cancer Free in 1.5 months with Ivermectin and Fenbendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-566?utm_campaign=email-half-post&r=18m8lm&utm_source=substack&utm_medium=email
0 · Reply
Latest News on BNTX
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 4 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 24, 2026, 6:45 AM EDT - 12 days ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 5:40 PM EDT - 26 days ago

BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

Mar 10, 2026, 3:39 PM EDT - 26 days ago

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 2:48 PM EDT - 26 days ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 1:29 PM EDT - 26 days ago

One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Mar 10, 2026, 8:40 AM EDT - 26 days ago

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 26 days ago

Scientists behind COVID-19 vaccine will depart BioNTech

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 7:18 AM EDT - 26 days ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 26 days ago

BioNTech Cofounders to Leave to Form New Company

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:49 AM EDT - 26 days ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:45 AM EDT - 26 days ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mar 10, 2026, 6:33 AM EDT - 26 days ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech: The Market Is Pricing Low Oncology Success

Feb 25, 2026, 9:46 AM EST - 5 weeks ago

BioNTech: The Market Is Pricing Low Oncology Success

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 5 weeks ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 6 weeks ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 2 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 10:45 PM EST - 2 months ago

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 2 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 3 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 3 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 9, 2025, 5:54 PM EST - 4 months ago

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 4 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 4 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 4 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 4 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 4 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 4 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 17, 2025, 6:17 PM EST - 4 months ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 5 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 5 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 5 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 5 months ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 5 months ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 5 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 5 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 5 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 5 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 6 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 6 months ago

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 6 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 7 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 7 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 7 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 7 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 7 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 7 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 7 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

I_Hate_Stock_Twits
I_Hate_Stock_Twits Apr. 3 at 6:42 PM
$BNTX This is why Robert Malone resigned. This recruitment stumble is a sham. No one will ever have to face the music. Still will never invest in this garbage. Shameful.
0 · Reply
Davidendz
Davidendz Apr. 3 at 1:37 PM
Biotech gets called “scam” on volatility, but that’s noise. What matters is data and execution. Across names like $BVAXF $BIOV.CSE,$MRNA, $BNTX, and $NVAX, it’s the same cycle: filings, catalysts, then price moves. Clinical progress > headlines.
0 · Reply
taxplanr
taxplanr Apr. 1 at 8:36 PM
What do you make of this testimony in front of the German Bundestag? $PFE $BNTX $MRNA https://www.instagram.com/reel/DWmYyx1jm4u/?igsh=MTBud3hycjBvM2J4ZA==
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 1 at 4:17 PM
$PFE $BNTX $MRNA $NVAX $SPY
2 · Reply
taxplanr
taxplanr Apr. 1 at 2:09 PM
Gastric tumors shrinking with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-cc3?utm_source=post-email-title&publication_id=1385328&post_id=192824123&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Apr. 1 at 2:02 PM
Metastases shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-mebendazole-fenbendazole-e15?utm_source=post-email-title&publication_id=1385328&post_id=192811753&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Pillemann1
Pillemann1 Apr. 1 at 8:45 AM
$BNTX https://www.ecdc.europa.eu/en/covid-19/variants-concern SARS-CoV-2 variants of concern as of 27 March 2026 Variant classification serves as an important communication tool for alerting EU/EEA countries about the emergence of SARS-CoV-2 variants with concerning properties likely to impact the epidemiological situation in the EU/EEA. The ECDC Strategic Analysis of Variants in Europe (SAVE) Working Group is a multidisciplinary team comprising of ECDC Experts working in Respiratory Viruses, Microbiology, Bioinformatics, Mathematical Modelling, Epidemic Intelligence, Emergency Preparedness and Response and Vaccine-Preventable Diseases and Immunisation. Currently meetings are held once per month to assess the observed or predicted impact of currently circulating and newly emerging SARS-CoV-2 variants in the EU/EEA and globally.
0 · Reply
PolycarpFX
PolycarpFX Mar. 31 at 10:34 PM
$BNTX
0 · Reply
taxplanr
taxplanr Mar. 31 at 4:31 PM
Bone tumors shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-454?utm_source=post-email-title&publication_id=1385328&post_id=192576453&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
1 · Reply
taxplanr
taxplanr Mar. 30 at 2:17 PM
Cancer Free in 1.5 months with Ivermectin and Fenbendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-566?utm_campaign=email-half-post&r=18m8lm&utm_source=substack&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 30 at 3:41 AM
Grok says C19 mRNA injections cause Cancer $BNTX $MRNA $PFE https://www.instagram.com/p/DWc1vbKjeD_/?igsh=cXU2eTBzYjhneG85
1 · Reply
_MoonNinja
_MoonNinja Mar. 29 at 8:19 PM
$VEEV $DG $VIV $BNTX watchlist 4
0 · Reply
taxplanr
taxplanr Mar. 27 at 7:04 PM
Ivermecting Fenbendazole and Mebendazole crushing Pancreatic Tumors in Romania $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-fenbendazole-mebendazole-0ea?utm_source=post-email-title&publication_id=1385328&post_id=192340675&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 27 at 6:06 PM
Ivermectin and Fenbendazole taking care of Lung Cancer $BNTX $MRNA $MRK $PFE https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-031?utm_source=post-email-title&publication_id=1385328&post_id=192330724&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 27 at 3:26 AM
C19 mRNA injections causing cancer CDC data $BNTX $MRNA $PFE https://www.instagram.com/reel/DWW1IZ0mkRJ/?igsh=MWt0M3ZvdndjcXI4eQ==
0 · Reply
taxplanr
taxplanr Mar. 26 at 1:51 PM
Beating Pancreatic Cancer in 12 months with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-568?utm_source=post-email-title&publication_id=1385328&post_id=192144835&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
twincam
twincam Mar. 26 at 12:40 PM
$BMY $RVMD $JANX $BNTX $BMY facing major patent cliffs (Eliquis, Opdivo) → forced to backfill with late-stage assets. Most strategic fits = oncology + next-gen IO + targeted therapies: $RVMD (KRAS Phase )$JANX (T-cell engagers, partnered), $BNTX (late-stage IO combos). Watch for: Phase 3 data + unusual call flow = early M&A signals. Big Pharma not optional here… it’s replace revenue or lose it.
0 · Reply
Vladdavceo
Vladdavceo Mar. 25 at 10:29 PM
$BNTX https://hackernoon.com/i-wired-800000-living-neurons-into-an-llm-heres-what-actually-happened $BIOLLM.X #BioLLM http://BioLLM.com $SOUN
0 · Reply
CarolSoukup997
CarolSoukup997 Mar. 25 at 9:23 PM
$BNTX $BMY $IBRX ngl imo it may be worth watching how those partnerships impact pipeline timing rather than calling it bearish right away btw
0 · Reply
taxplanr
taxplanr Mar. 25 at 9:18 PM
$BNTX $MRNA $PFE $MRK
0 · Reply
wheresdannynow
wheresdannynow Mar. 25 at 6:39 PM
mRNA headlines belong to $MRNA $BNTX, but innovation runs deeper. $BIOV’s DPX just landed a vet collab and delivered encouraging ovarian and bladder data. Bullish long-term setup. https://finance.yahoo.com/news/biovaxys-ai-guided-mrna-immunotherapy-120000399.html
0 · Reply
NasdaqPulse
NasdaqPulse Mar. 25 at 4:38 PM
$BNTX — JEFFERIES SAYS BUY! $138 PT! While the market sleeps on BioNTech, the pros are holding the line. Jefferies reiterates BUY with a $138 price target. Current: $88.64 Upside to PT: +55.7% 50dma: $104.95 — that's $16 ABOVE current price This is a DISCONNECT. The stock is trading 15% below its 50dma. The last time we saw this setup? It ripped. The mRNA machine is bigger than COVID. Oncology pipeline. Personalized cancer therapies. This is a $21B company with a massive cash pile and the most advanced mRNA platform on the planet. 13 Buy ratings. 4 Holds. 1 Sell. The market is pricing this like it's 2022. It's not. Accumulate aggressively below $90.
0 · Reply